Literature DB >> 26091320

Chronic restraint stress after injury and shock is associated with persistent anemia despite prolonged elevation in erythropoietin levels.

Letitia E Bible1, Latha V Pasupuleti, Amy V Gore, Ziad C Sifri, Kolenkode B Kannan, Alicia M Mohr.   

Abstract

BACKGROUND: Following severe traumatic injury, critically ill patients have a prolonged hypercatacholamine state that is associated with bone marrow (BM) dysfunction and persistent anemia. However, current animal models of injury and shock result in a transient anemia. Daily restraint stress (chronic stress [CS]) has been shown to increase catecholamines. We hypothesize that adding CS following injury or injury and shock in rats will prolong the hypercatecholaminemia and prolong the initial anemia, despite elevated erythropoietin (EPO) levels.
METHODS: Male Sprague-Dawley rats (n = 6-8 per group) underwent lung contusion (LC) or combined LC/hemorrhagic shock (LCHS) followed by 6 days of CS. CS consisted of a 2-hour restraint period interrupted with repositioning and alarms every 30 minutes. At 7 days, urine was assessed for norepinephrine (NE) levels, blood for EPO and hemoglobin (Hgb), and BM for erythroid progenitor growth.
RESULTS: Animals undergoing LC or combined LCHS predictably recovered by Day 7; urine NE, EPO, and Hgb levels were normal. The addition of CS to LC and LCHS models was associated with a significant elevation in NE on Day 6. The addition of CS to LC led to a persistent 20% to 25% decrease in the growth of BM hematopoietic progenitor cells. These findings were further exaggerated when CS was added following LCHS, resulting in a 20%q to 40% reduction in BM erythroid progenitor colony growth and a 20% decrease in Hgb when compared with LCHS alone.
CONCLUSION: Exposing injured animals to CS results in prolonged elevation of NE and EPO, which is associated with worsening BM erythroid function and persistent anemia. Chronic restraint stress following injury and shock provides a clinically relevant model to further evaluate persistent injury-associated anemia seen in critically ill trauma patients. Furthermore, alleviating CS after severe injury is a potential therapeutic target to improve BM dysfunction and anemia.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26091320      PMCID: PMC4902106          DOI: 10.1097/TA.0000000000000686

Source DB:  PubMed          Journal:  J Trauma Acute Care Surg        ISSN: 2163-0755            Impact factor:   3.313


  34 in total

1.  Modulation of natural killer cell activity by restraint stress during an influenza A/PR8 infection in mice.

Authors:  John Hunzeker; David A Padgett; Patricia A Sheridan; Firdaus S Dhabhar; John F Sheridan
Journal:  Brain Behav Immun       Date:  2004-11       Impact factor: 7.217

2.  Anemia during and at discharge from intensive care: the impact of restrictive blood transfusion practice.

Authors:  Timothy S Walsh; Robert J Lee; Caroline R Maciver; Magnus Garrioch; Fiona Mackirdy; Alexander R Binning; Stephen Cole; D Brian McClelland
Journal:  Intensive Care Med       Date:  2005-11-23       Impact factor: 17.440

Review 3.  The stress response of critical illness.

Authors:  J Epstein; M J Breslow
Journal:  Crit Care Clin       Date:  1999-01       Impact factor: 3.598

4.  Environmental stress-induced gastrointestinal permeability is mediated by endogenous glucocorticoids in the rat.

Authors:  J B Meddings; M G Swain
Journal:  Gastroenterology       Date:  2000-10       Impact factor: 22.682

5.  Mucosal wound healing is impaired by examination stress.

Authors:  P T Marucha; J K Kiecolt-Glaser; M Favagehi
Journal:  Psychosom Med       Date:  1998 May-Jun       Impact factor: 4.312

Review 6.  Mechanisms of Disease: erythropoietin resistance in patients with both heart and kidney failure.

Authors:  Karien van der Putten; Branko Braam; Kim E Jie; Carlo A J M Gaillard
Journal:  Nat Clin Pract Nephrol       Date:  2008-01

7.  Acute adrenergic stress inhibits proliferation of murine hematopoietic progenitor cells via p38/MAPK signaling.

Authors:  Elisabeth Schraml; Robert Fuchs; Petra Kotzbeck; Johannes Grillari; Konrad Schauenstein
Journal:  Stem Cells Dev       Date:  2009-03       Impact factor: 3.272

8.  The CRIT Study: Anemia and blood transfusion in the critically ill--current clinical practice in the United States.

Authors:  Howard L Corwin; Andrew Gettinger; Ronald G Pearl; Mitchell P Fink; Mitchell M Levy; Edward Abraham; Neil R MacIntyre; M Michael Shabot; Mei-Sheng Duh; Marc J Shapiro
Journal:  Crit Care Med       Date:  2004-01       Impact factor: 7.598

9.  Iron status, anemia, and plasma erythropoietin levels in acute and chronic mouse models of colitis.

Authors:  Patsy R Carter; Megan N Watts; Melissa Kosloski-Davidson; Kanchanjunga Prasai; Matthew B Grisham; Norman R Harris
Journal:  Inflamm Bowel Dis       Date:  2013-05       Impact factor: 5.325

10.  Heart failure-associated anemia: bone marrow dysfunction and response to erythropoietin.

Authors:  Willem-Peter T Ruifrok; Cheng Qian; Herman H W Silljé; Harry van Goor; Dirk J van Veldhuisen; Wiek H van Gilst; Rudolf A de Boer
Journal:  J Mol Med (Berl)       Date:  2010-12-30       Impact factor: 4.599

View more
  25 in total

1.  Characterization of erythropoietin and hepcidin in the regulation of persistent injury-associated anemia.

Authors:  Ines G Alamo; Kolenkode B Kannan; Michael A Smith; Philip A Efron; Alicia M Mohr
Journal:  J Trauma Acute Care Surg       Date:  2016-10       Impact factor: 3.313

Review 2.  The future of murine sepsis and trauma research models.

Authors:  Philip A Efron; Alicia M Mohr; Frederick A Moore; Lyle L Moldawer
Journal:  J Leukoc Biol       Date:  2015-06-01       Impact factor: 4.962

3.  Mediators of Prolonged Hematopoietic Progenitor Cell Mobilization After Severe Trauma.

Authors:  Getasha D Doobay; Elizabeth S Miller; Camille G Apple; Tyler J Loftus; Kolenkode B Kannan; Philip A Efron; Alicia M Mohr
Journal:  J Surg Res       Date:  2020-12-26       Impact factor: 2.192

4.  Persistent injury-associated anemia: the role of the bone marrow microenvironment.

Authors:  Jessica K Millar; Kolenkode B Kannan; Tyler J Loftus; Ines G Alamo; Jessica Plazas; Philip A Efron; Alicia M Mohr
Journal:  J Surg Res       Date:  2017-03-31       Impact factor: 2.192

5.  Daily propranolol administration reduces persistent injury-associated anemia after severe trauma and chronic stress.

Authors:  Ines G Alamo; Kolenkode B Kannan; Letitia E Bible; Tyler J Loftus; Harry Ramos; Philip A Efron; Alicia M Mohr
Journal:  J Trauma Acute Care Surg       Date:  2017-04       Impact factor: 3.313

6.  Clonidine reduces norepinephrine and improves bone marrow function in a rodent model of lung contusion, hemorrhagic shock, and chronic stress.

Authors:  Ines G Alamo; Kolenkode B Kannan; Harry Ramos; Tyler J Loftus; Philip A Efron; Alicia M Mohr
Journal:  Surgery       Date:  2016-10-11       Impact factor: 3.982

7.  Systemic Regulation of Bone Marrow Stromal Cytokines After Severe Trauma.

Authors:  Elizabeth S Miller; Tyler J Loftus; Kolenkode B Kannan; Jessica M Plazas; Philip A Efron; Alicia M Mohr
Journal:  J Surg Res       Date:  2019-06-14       Impact factor: 2.192

8.  Persistent injury-associated anemia and aging: Novel insights.

Authors:  Tyler J Loftus; Kolenkode B Kannan; Christy S Carter; Jessica M Plazas; Juan C Mira; Scott C Brakenridge; Christiaan Leeuwenburgh; Philip A Efron; Alicia M Mohr
Journal:  J Trauma Acute Care Surg       Date:  2018-03       Impact factor: 3.313

9.  Persistent injury-associated anemia in aged rats.

Authors:  Tyler J Loftus; Kolenkode B Kannan; Christy S Carter; Jessica M Plazas; Juan C Mira; Scott C Brakenridge; Christiaan Leeuwenburgh; Philip A Efron; Alicia M Mohr
Journal:  Exp Gerontol       Date:  2018-01-04       Impact factor: 4.032

10.  The effects of selective beta-adrenergic blockade on bone marrow dysfunction following severe trauma and chronic stress.

Authors:  Elizabeth S Miller; Camille G Apple; Kolenkode B Kannan; Zackary M Funk; Philip A Efron; Alicia M Mohr
Journal:  Am J Surg       Date:  2020-07-25       Impact factor: 2.565

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.